Recombinant granulocyte-CSF (G-CSF) and granulocyte–macrophage-CSF (GM-CSF) have now been used to increase dangerously low white blood cell levels in many millions of cancer patients following ...

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third ...

Virus linked to common cold could help treat aggressive brain tumours - Scientists say new approach offers ‘a way forward’ ...

One particular company with an earlier topline Phase 2 readout on 100 patients with pulmonary sarcoidosis is Roivant Sciences (ROIV), with its anti-GM-CSF monoclonal antibody namilumab.

Danyelza, scientific name naxitamab, is approved in combination, with granulocyte-macrophage colony stimulating factor (GM-CSF) for R/R High-risk neuroblastoma in a pediatric setting. R/R HR NB ...

Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by ...

【导读】UVB辐射会诱发氧化应激、DNA损伤和炎症，导致皮肤皱纹、屏障功能受损和致癌风险增加。最近的研究表明，间充质干细胞（MSCs）对各种皮肤病具有显著的治疗潜力。鉴于细胞外囊泡（EV）可以将不同的货物递送到受体细胞并引发类似的治疗效果，团队研究了 ...

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer ...

BT-001 replicated in the tumor and expressed the encoded GM-CSF and anti-CTLA-4 transgenes. Notably, BT-001 in combination with pembrolizumab showed first signs of efficacy in 2 out of 6 patients, ...